- Home
- BIDU vs SLRX Comparison
BIDU vs SLRX Comparison
Compare BIDU & SLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIDU | SLRX |
|---|---|---|
| Founded | 2000 | N/A |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.9B | 3.6M |
| IPO Year | 2005 | N/A |
Fundamental Metrics
Financial Performance| Metric | BIDU | SLRX |
|---|---|---|
| Price | $146.88 | $0.84 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 13 | 0 |
| Target Price | ★ $146.08 | N/A |
| AVG Volume (30 Days) | ★ 3.1M | 348.2K |
| Earning Date | 02-17-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.25 | N/A |
| Revenue | ★ $18,325,514,127.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.78 | N/A |
| P/E Ratio | $45.08 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $74.71 | $0.51 |
| 52 Week High | $151.43 | $108.00 |
Technical Indicators
Market Signals| Indicator | BIDU | SLRX |
|---|---|---|
| Relative Strength Index (RSI) | 70.47 | 47.16 |
| Support Level | $129.30 | $0.51 |
| Resistance Level | $151.43 | $0.68 |
| Average True Range (ATR) | 3.71 | 0.06 |
| MACD | 2.72 | 0.07 |
| Stochastic Oscillator | 86.86 | 82.81 |
Price Performance
Historical ComparisonAbout BIDU Baidu Inc. ADS
Baidu is the largest internet search engine in China with over 50% share of the search engine market in 2024 per web analytics firm, Statcounter. The firm generated 70% of core revenue from online marketing services from its search engine in 2024. Outside its search engine, Baidu is a technology-driven company and its other major growth initiatives are artificial intelligence cloud, video streaming services, voice recognition technology, and autonomous driving.
About SLRX Salarius Pharmaceuticals Inc.
Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.